Raphael Pharmaceutical Inc. (RAPH)
OQB · Healthcare · Drug Manufacturers - Specialty & Generic
$1.40
+0.00%
Closing price as of 2026-09-10 · Source: TEK2day Finance
Key Metrics
Market Cap
$28.2M
Shares Outstanding
20.2M
Exchange
OQB
Currency
USD
About Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. Raphael Pharmaceutical Inc., is headquartered in Jaffa, Israel.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (251K) | (254K) | (223K) | (199K) |
| Net Income | (255K) | (273K) | (229K) | (223K) |
| Diluted EPS | $-0.01 | N/A | $-0.01 | $-0.01 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (3.3M) | (1.3M) | (1.5M) | (1.2M) |
| Net Income | (3.4M) | (1.3M) | (1.5M) | (1.3M) |
| Diluted EPS | $-0.23 | $-0.08 | $-0.08 | $-0.07 |